{"id":39555,"date":"2020-12-09T07:25:57","date_gmt":"2020-12-09T07:25:57","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=39555"},"modified":"2020-12-10T19:38:34","modified_gmt":"2020-12-10T19:38:34","slug":"hydroxychloroquine-has-no-benefit-on-symptoms-at-14-days","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/39555","title":{"rendered":"Hydroxychloroquine has no benefit on symptoms at 14 days"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><b><span lang=\"EN-US\"><strong><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" width=\"231\" height=\"142\" \/><\/strong><\/span><\/b><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p class=\"HTBsubhead2articletitle\"><strong>Although hydroxychloroquine is no longer being studied as either treatment or prophylaxis for COVID-19 there will continue to be studies that add to this negative data set that are worth briefly reporting.<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">In this case, a randomised, blinded, placebo-controlled study that planned to enrol ~ 500 adults hospitalised with COVID-19 and respiratory symptoms was stopped early (after 479 participants had been enrolled) due to no evidence of effect. The primary endpoint was change in symptoms at day 14 based on a 7-category ordinal scale.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">The study concluded \u201cthese findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalised adults\u201d.<\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Reference<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Self WH et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: <\/span><span lang=\"EN-US\">A randomized clinical trial. JAMA<i>.\u00a0<\/i>2020;324(21):2165-2176. doi:10.1001\/jama.2020.2224. (9 November 2020).<br \/>\n<\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/10.1001\/jama.2020.22240\">https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/10.1001\/jama.2020.22240<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Although hydroxychloroquine is no longer being studied as either treatment or prophylaxis for COVID-19 there will continue to be studies that add to this negative data set that are worth briefly reporting. In this case, a &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-39555","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/39555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=39555"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/39555\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=39555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=39555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=39555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}